OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers Research & Therapy is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	547
Retraction Note: Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer’s disease pathogenesis	166
Diabetes status, duration, and risk of dementia among ischemic stroke patients	151
APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia	149
Targeting early tau pathology: probiotic diet enhances cognitive function and reduces inflammation in a preclinical Alzheimer’s model	127
Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit	117
Is the clinical phenotype impact the prognosis in dementia with Lewy bodies?	113
Kidney function, albuminuria, and their modification by genetic factors and risk of incident dementia in UK Biobank	109
Experiences of and recommendations on clinical trial design in Alzheimer’s disease from the participant’s point of view: a mixed-methods study in two clinical trial centers in the Netherlands	98
Association of outer retinal and choroidal alterations with neuroimaging and clinical features in posterior cortical atrophy	91
Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts	87
The course of primary progressive aphasia diagnosis: a cross-sectional study	86
Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation	80
Molecular landscape of the overlap between Alzheimer’s disease and somatic insulin-related diseases	79
Longitudinal change in ATN biomarkers in cognitively normal individuals	79
Prognostic model for predicting Alzheimer’s disease conversion using functional connectome manifolds	78
Intestinal endogenous metabolites affect neuroinflammation in 5×FAD mice by mediating “gut-brain” axis and the intervention with Chinese Medicine	78
The impact of incident stroke on cognitive trajectories in later life	76
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912	71
Gossypetin ameliorates 5xFAD spatial learning and memory through enhanced phagocytosis against Aβ	69
Association of accelerated long-term forgetting and senescence-related blood-borne factors in asymptomatic individuals from families with autosomal dominant Alzheimer’s disease	67
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	66
Retinal optical coherence tomography intensity spatial correlation features as new biomarkers for confirmed Alzheimer’s disease	66
Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia	65
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	65

Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer’s disease	61
Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update	60
Mesial temporal tau in amyloid-β-negative cognitively normal older persons	60
Cerebrospinal fluid β2-microglobulin promotes the tau pathology through microglia–astrocyte communication in Alzheimer's disease	59
Alzheimer’s pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome	59
Uncovering the epigenetic regulatory clues of PRRT1 in Alzheimer’s disease: a strategy integrating multi-omics analysis with explainable machine learning	59
Exploring shared neural substrates underlying cognition and gait variability in adults without dementia	56
Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography	55
Investigating the power of eyes open resting state EEG for assisting in dementia diagnosis	54
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease	52
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	50
Synergistic interaction of high blood pressure and cerebral beta-amyloid on tau pathology	49
Tau-PET pathology in the subregions of the amygdala and its associations with cognitive performance and neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease	49
A novel age-informed approach for genetic association analysis in Alzheimer’s disease	48
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	48
A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation	48
High-intensity walking in midlife is associated with improved memory in physically capable older adults	47
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	47
Association of cortical and subcortical microstructure with disease severity: impact on cognitive decline and language impairments in frontotemporal lobar degeneration	47
The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury	47
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum	47
The relation of a cerebrospinal fluid profile associated with Alzheimer’s disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy	46